MacroGenics (MGNX) Competitors

MacroGenics (NASDAQ:MGNX) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking and institutional ownership.

Does the media refer more to MGNX or ORKA?

In the previous week, Oruka Therapeutics had 7 more articles in the media than MacroGenics. MarketBeat recorded 12 mentions for Oruka Therapeutics and 5 mentions for MacroGenics. MacroGenics' average media sentiment score of 1.09 beat Oruka Therapeutics' score of 0.85 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of MGNX or ORKA?

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 13.0% of MacroGenics shares are held by company insiders. Comparatively, 22.7% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has higher earnings and valuation, MGNX or ORKA?

Oruka Therapeutics has lower revenue, but higher earnings than MacroGenics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$148.34M	0.71	-$9.06M	-$1.08	-1.56
Oruka Therapeutics	N/A	N/A	-$5.34M	-$5.79	-1.74

Which has more volatility & risk, MGNX or ORKA?

MacroGenics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Do analysts recommend MGNX or ORKA?

MacroGenics currently has a consensus target price of $7.38, indicating a potential upside of 338.99%. Oruka Therapeutics has a consensus target price of $39.86, indicating a potential upside of 295.02%. Given MacroGenics' higher probable upside, research analysts clearly believe MacroGenics is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	0 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.36
Oruka Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22

Does the MarketBeat Community favor MGNX or ORKA?

MacroGenics received 409 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 62.10% of users gave MacroGenics an outperform vote.

Company	Underperform	Outperform
MacroGenics	Outperform Votes 426 62.10%	Underperform Votes 260 37.90%
Oruka Therapeutics	Outperform Votes 17 100.00%	Underperform Votes No Votes

Is MGNX or ORKA more profitable?

Oruka Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. Oruka Therapeutics' return on equity of -24.96% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-69.07%	-89.42%	-38.57%
Oruka Therapeutics	N/A	-24.96%	-21.22%

Summary

Oruka Therapeutics beats MacroGenics on 10 of the 18 factors compared between the two stocks.